The diagnostic value of CT-guided percutaneous lung biopsy in atypical pulmonary hamartoma and pulmonary sclerosing pneumocytoma.
CT-guided percutaneous biopsy correctly diagnosed 89.5% of atypical hamartoma and sclerosing pneumocytoma cases.
The diagnostic value of CT-guided percutaneous lung biopsy in atypical pulmonary hamartoma and pulmonary sclerosing pneumocytoma.
This study aims to evaluate the clinical utility of computed tomography-guided percutaneous lung biopsy (CT-PLB) in the diagnosis of atypical pulmonary hamartoma (atypical pulmonary hamartoma) and pulmonary sclerosing pneumocytoma (pulmonary sclerosing pneumocytoma).
This retrospective study analyzed 19 patients with pulmonary nodules who underwent CT-PLB at our hospital between October 2016 and August 2019.
biopsy correctly identified most cases, missing about 1 in 10
The diagnostic accuracy was 88.9% (8/9) in the atypical pulmonary hamartoma group and 90.0% (9/10) in the pulmonary sclerosing pneumocytoma group.
Complications included one case of minimal pneumothorax in the pulmonary sclerosing pneumocytoma group and one case of mild hemoptysis in the atypical pulmonary hamartoma group.
Additionally, 14 patients experienced mild to moderate pulmonary hemorrhage, including 8 cases (5 mild, 3 moderate) in the atypical pulmonary hamartoma group and 6 cases (all mild) in the pulmonary sclerosing pneumocytoma group.
No severe complications, such as pleural reactions, occurred in any patient.
CT-PLB demonstrates high clinical diagnostic value for both atypical pulmonary hamartoma and pulmonary sclerosing pneumocytoma. The procedure is safe, reliable, and associated with few complications.
Thus, it can serve as a valuable tool for preoperative clinical diagnosis.